thalidomide has been researched along with navitoclax in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hillmen, P | 1 |
| Abdul-Hay, M; Desai, AV; El-Bakkar, H | 1 |
| Rosen, ST; Siddiqi, T | 1 |
2 review(s) available for thalidomide and navitoclax
| Article | Year |
|---|---|
Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Topics: Adenine; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cyclic N-Oxides; Flavonoids; Humans; Immunologic Factors; Indolizines; Isoquinolines; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Purines; Pyrazoles; Pyridinium Compounds; Pyrimidines; Quinazolinones; Receptors, Antigen, T-Cell; Sulfonamides; Thalidomide | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome | 2015 |
1 other study(ies) available for thalidomide and navitoclax
| Article | Year |
|---|---|
Targeted therapy for chronic lymphocytic leukemia: a glimpse into the future.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mutation; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Thalidomide; Thionucleotides; Tumor Suppressor Protein p53 | 2012 |